최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Tuberculosis and respiratory diseases : TRD = 결핵 및 호흡기 질환, v.71 no.1, 2011년, pp.1 - 7
Many findings suggest that chronic obstructive pulmonary disease (COPD) imposes an enormous burden on patients, health-care professionals and society. COPD contributes to morbidity and mortality and to a significant use of health-care resources. In spite of a higher prevalence of COPD in Korea, the ...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
MMRC 호흡곤란점수는 어떠한 평가도구로 이용되는가? | 또한 호흡곤란지수 평가도구로 이용되는 MMRC 호흡곤란점수(Modified Research Council dyspnea score)가 있는데 평가기준이 범주형으로 되어 있어 정량적으로 호흡곤란 정도를 평가기는 어렵다6. | |
호흡곤란-12 (dyspnea12)이 호흡곤란을 정략적으로 평가할 수 있는 이유는 무엇인가? | 다른 호흡곤란의 평가도구로 호흡곤란-12 (dyspnea12)가 있는데 12개 항목으로 구성되어 있으며, 각 항목은 0∼3점으로 분류하여 총 0∼36점까지 평가할 수 있어 호흡곤란을 정략적으로 평가할 수 있다7. 본 연구는 CAT 한국어판과 호흡곤란-12 한국어판에 대한 신뢰도와 타당성 검증을 위한 것이다. | |
만성 폐쇄성 폐질환 환자를 진단하고 치료경과를 모니터하는데 전통적으로 사용하는 것은 무엇인가? | COPD 환자를 진단하고 치료경과를 모니터하는데 전통적으로 폐기능 검사를 주로 사용하고 있으나 폐기능 검사만으로 평가하는 것보다는 삶의 질, 운동능력, 증상의 악화 등 여러 면에서 평가하는 것이 예후를 예측하는데 더 중요한 것으로 알려져 있다4. 이러한 여러 지표를 평가하는 방법으로 SGRQ (Saint George's Respiratory Questionnaire)를 축약하여 COPD assessment test (CAT)가 개발되어 있으며5 최근 한국어판이 언어학적 평가를 거쳐 공개되었다. |
Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey, 2008. Respirology 2011;16:659-65.
Kim DS, Kim YS, Jung KS, Chang JH, Lim CM, Lee JH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: a population-based spirometry survey. Am J Respir Crit Care Med 2005;172:842-7.
Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-12.
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J 2009;34:648-54.
Stoller JK, Ferranti R, Feinstein AR. Further specification and evaluation of a new clinical index for dyspnea. Am Rev Respir Dis 1986;134:1129-34.
Yorke J, Moosavi SH, Shuldham C, Jones PW. Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax 2010;65:21-6.
Douglas SL, Daly BJ, Gordon N, Brennan PF. Survival and quality of life: short-term versus long-term ventilator patients. Crit Care Med 2002;30:2655-62.
National Heart, Lung and Blood Institute; National Institutes of Health. Morbidity and mortality: 2007 chart book on cardiovascular, lung and blood diseases [internet]. Bethesda, MD: National Institutes of Health; 2007 [cited 2010 Oct 14]. Available from: http://www.nhlbi.nih.gov/resources/docs/07a-chtbk.pdf.
American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;152:S77-121.
Global Initiative for Chronic Obstructive Lung disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease [internet]. [place unknown]: GOLD; c2009. [cited 2009 Nov 18]. Available from: http//www.goldcopd.org.
Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
Kwon YS, Chi SY, Shin HJ, Kim EY, Yoon BK, Ban HJ, et al. Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci 2010;25:1487-91.
Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005;60:605-9.
Barbera JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;149:423-9.
Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002;19:632-8.
Ballou SP, Lozanski G. Induction of inflammatory cytokine release from cultured human monocytes by C-reactive protein. Cytokine 1992;4:361-8.
Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993;82:513-20.
Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-33.
Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-5.
Allen SW, Chatfield BA, Koppenhafer SA, Schaffer MS, Wolfe RR, Abman SH. Circulating immunoreactive endothelin- 1 in children with pulmonary hypertension. Association with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 1993;148:519-22.
Ryu YJ, Chun EM, Lee JH, Chang JH. Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med 2010;25:51-7.
Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. Qual Life Res 2002;11:309-16.
Dahlen I, Janson C. Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Chest 2002;122:1633-7.
Jo KW, Ra SW, Chae EJ, Seo JB, Kim NK, Lee JH, et al. Three phenotypes of obstructive lung disease in the elderly. Int J Tuberc Lung Dis 2010;14:1481-8.
Viegi G, Matteelli G, Angino A, Scognamiglio A, Baldacci S, Soriano JB, et al. The proportional Venn diagram of obstructive lung disease in the Italian general population. Chest 2004;126:1093-101.
Lee JS, Huh JW, Chae EJ, Seo JB, Ra SW, Lee JH, et al. Predictors of pulmonary function response to treatment with salmeterol/fluticasone in patients with chronic obstructive pulmonary disease. J Korean Med Sci 2011;26:379-85.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-91.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
BTS guidelines for the management of chronic obstructive pulmonary disease. The COPD guidelines Group of the Standards of Care Committee of the BTS. Thorax 1997;52(Suppl 5):S1-28.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8.
Lee JH, Lee YK, Kim EK, Kim TH, Huh JW, Kim WJ, et al. Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. Respir Med 2010;104:542-9.
Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 1991;114:216-23.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.